| Followers | 34 |
| Posts | 2917 |
| Boards Moderated | 0 |
| Alias Born | 02/18/2005 |
Wednesday, March 26, 2025 12:20:21 PM
Shortly after FDA approval, Humacyte began receiving requests for quotations for Symvess from hospitals. Twenty-one hospitals have already initiated the VAC approval process, with additional hospitals expected to commence the process. These hospitals are a mix of leading trauma centers that were participants in Humacyte clinical studies combined with institutions newly introduced to Symvess.
Bullish
Recent HUMA News
- Strong Earnings and Biotech Resilience Define the Midweek Momentum • GlobeNewswire Inc. • 11/12/2025 04:00:36 PM
- D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering • ACCESS Newswire • 10/14/2025 12:30:00 PM
- Humacyte shares plunge after announcing $60 million registered direct offering • IH Market News • 10/07/2025 02:01:56 PM
- Humacyte shares climb 6% after first Symvess sale to U.S. military hospital • IH Market News • 07/23/2025 03:24:35 PM
